Goelzer Investment Management Inc. Buys 12,976 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Goelzer Investment Management Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,040 shares of the biopharmaceutical company’s stock after buying an additional 12,976 shares during the period. Goelzer Investment Management Inc.’s holdings in Gilead Sciences were worth $5,912,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of the company. Hampstead Capital LLP bought a new position in Gilead Sciences during the fourth quarter valued at about $2,936,000. City Financial Investment Co Ltd bought a new position in Gilead Sciences during the fourth quarter valued at about $8,658,000. Bogle Investment Management L P DE raised its position in Gilead Sciences by 5.3% in the fourth quarter. Bogle Investment Management L P DE now owns 152,106 shares of the biopharmaceutical company’s stock valued at $10,892,000 after buying an additional 7,688 shares during the last quarter. Drexel Morgan & Co. raised its position in Gilead Sciences by 36.5% in the fourth quarter. Drexel Morgan & Co. now owns 7,480 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 2,000 shares during the last quarter. Finally, Moloney Securities Asset Management LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $457,000. Institutional investors and hedge funds own 74.05% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 74.39 on Tuesday. The stock has a market capitalization of $97.21 billion, a P/E ratio of 7.86 and a beta of 1.20. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85. The firm’s 50-day moving average price is $68.32 and its 200-day moving average price is $68.63.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.42 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 29th. Shareholders of record on Friday, June 16th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 21.99%.
A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday. BMO Capital Markets reiterated a “hold” rating and issued a $72.00 price objective on shares of Gilead Sciences in a research report on Friday. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective on the stock in a research report on Monday, June 26th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Fifteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $80.09.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock worth $6,230,610 over the last three months. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.